The *Cacna1h* mutation in the GAERS model of absence epilepsy enhances T-type Ca\(^{2+}\) currents by altering calnexin-dependent trafficking of Ca\(_v\)3.2 channels

Juliane Proft\(^1\), Yuriy Rzhepetskyy\(^1\), Joanna Lazniewska\(^1\), Fang-Xiong Zhang\(^2\), Stuart M. Cain\(^3\), Terrance P. Snutch\(^3\), Gerald W. Zamponi\(^2\) & Norbert Weiss\(^1\)

Low-voltage-activated T-type calcium channels are essential contributors to the functioning of thalamocortical neurons by supporting burst-firing mode of action potentials. Enhanced T-type calcium conductance has been reported in the Genetic Absence Epilepsy Rat from Strasbourg (GAERS) and proposed to be causally related to the overall development of absence seizure activity. Here, we show that calnexin, an endoplasmic reticulum integral membrane protein, interacts with the III-IV linker region of the Ca\(_v\)3.2 channel to modulate the sorting of the channel to the cell surface. We demonstrate that the GAERS missense mutation located in the Ca\(_v\)3.2 III-IV linker alters the Ca\(_v\)3.2/calnexin interaction, resulting in an increased surface expression of the channel and a concomitant elevation in calcium influx. Our study reveals a novel mechanism that controls the expression of T-type channels, and provides a molecular explanation for the enhancement of T-type calcium conductance in GAERS.

Generalized non-motor epilepsies are often associated with an hereditary component\(^1\). They are characterized by the occurrence of spontaneous convulsive or nonconvulsive seizures with sudden bilateral synchronous spike and wave discharges (SWDs) on the electroencephalogram (EEG)\(^2\). Absence seizures are a type of nonconvulsive generalized seizures, which involve brief and sudden lapses of consciousness, usually associated with generalized 3–4 Hz SWDs\(^3\). The Genetic Absence Epilepsy Rat from Strasbourg (GAERS) is a well-validated rodent model of absence epilepsy\(^4\). Absence-like seizures in GAERS are manifested by spontaneous behavioral arrest and staring, clonic twitching of the vibrissae, and high-amplitude SWDs\(^3\). As for human generalized non-motor epilepsies, SWDs in GAERS are inherited, and notably segregate with a missense mutation in the gene *Cacna1h* encoding for the voltage-gated Ca\(_v\)3.2 T-type calcium channel\(^6\).

T-type channels are low-voltage-gated calcium channels that operate near the resting electrical membrane potential of nerve cells\(^7\). Although a preceding period of hyperpolarization may be required to recruit T-type channels from inactivation, they are typically triggered by subthreshold membrane depolarizations to generate a Ca\(^{2+}\) transient which in turn gives rise to high frequency bursts of action potentials that support various forms of neuronal rhythmogenesis\(^8\)–\(^11\). These aspects of T-type channel function are of direct relevance to the functioning of the thalamocortical network, a brain circuit that is critically involved in the development and propagation of SWDs\(^12\)–\(^14\).

Several lines of evidence support a causal implication of T-type channels in the pathogenesis of epilepsy. First, gain-of-function polymorphisms in the human *CACNA1H* gene segregate in patients with childhood and juvenile absence epilepsy\(^15\)–\(^20\). Second, direct inhibition of T-type channels (Ca\(_v\)3.1, Ca\(_v\)3.2 and Ca\(_v\)3.3 isoforms)
by small organic molecules reduces thalamic burst firing and suppresses seizures in rodent models of absence, temporal lobe epilepsies\(^1\), and other types of seizures\(^2\). Third, T-type calcium channel inhibitors are effective in the treatment of absence seizures in humans\(^6\). Finally, T-type Ca\(^{2+}\) conductances are elevated in thalamic neurons of several rodent models of absence epilepsy\(^25\)−\(^27\), whereas once lacking the Ca\(_{3.1}\) T-type channel exhibit increased resistance to absence seizures\(^28\). The causal link between a primary elevation of T-type Ca\(^{2+}\) conductances and the development of absence epilepsy is further supported by the observation that genetic enhancement of Ca\(_{3.1}\) channel expression in mice is sufficient to induce an epileptic phenotype\(^29\).

The GAERS Cacna1h missense mutation results in a splice-variant specific gain-of-function of Ca\(_{3.2}\) currents that exhibit significantly faster recovery from channel inactivation and greater charge transference during high-frequency bursts\(^6\). However, consistent with the polygenic nature of generalized non-motor epilepsies the Cacna1h missense mutation does not by itself entirely account for absence seizure activity in GAERS. Other reported alterations in GAERS include elevated levels of thalamic Ca\(_{3.2}\) mRNA expression\(^30\) and whole cell T-type currents\(^35\), although the genetic and molecular mechanisms by which upregulation of T-type channel activity might occur in GAERS and other rodent models of absence epilepsy remain unknown.

It is well described that calnexin, a type I endoplasmic reticulum integral membrane protein and molecular chaperone, is responsible for the folding, quality control and sorting of newly-synthesized (glyco)proteins\(^31\). Although T-type channels undergo asparagine (N)–linked glycosylation\(^32\)−\(^35\), the role of calnexin in the biogenesis and sorting of T-type channels is not understood. Here we show that calnexin binds to and modulates trafficking of Ca\(_{3.2}\) channels to the cell surface by altering the retention of the channel in the endoplasmic reticulum (ER). In addition, we show that calnexin-dependent regulation of Ca\(_{3.2}\) channels is disrupted by the GAERS mutation, thereby leading to an increased surface expression of T-type channels. These results thus reveal a mechanism for the enhanced T-type Ca\(^{2+}\) conductance in GAERS, and provide new fundamental knowledge into the biogenesis and molecular trafficking of T-type channels.

### Results

**Calnexin associates with Ca\(_{3.2}\) to modulate channel expression and function.** To determine whether T-type channels and calnexin associate at the protein level, we performed co-immunoprecipitation experiments of Ca\(_{3.2}\) with calnexin from wild type (WT) versus Ca\(_{3.2}\) knock out (KO) brains. As shown in Fig. 1A, a specific anti-calnexin antibody precipitated Ca\(_{3.2}\) from WT mouse brain homogenate, suggesting the existence of T-type channel/calnexin complexes in neuronal tissue. Note that the immunoprecipitated reactive species above 250 kDa that corresponds to the Ca\(_{3.2}\) channel is not present in the co-immunoprecipitation performed from Ca\(_{3.2}\) KO brain, thus demonstrating the specificity of the anti-Ca\(_{3.2}\) antibody used in these experiments. Furthermore, western blot analysis of Ca\(_{3.2}\) from brain homogenate before and after immunoprecipitation indicated that most of Ca\(_{3.2}\) channels are immunoprecipitated by calnexin (Fig. 1B). In contrast, Ca\(_{3.2}\) does not specifically interact with calreticulin and binding immunoglobulin protein (BiP), two other endoplasmic reticulum proteins known to interact with newly synthesized proteins (Fig. S1). The Ca\(_{3.2}\)/calnexin interaction was also observed in tsA-201 cells expressing a recombinant HA-tagged human Ca\(_{3.2}\) channel (HA-hCa\(_{3.2}\)) (Fig. 1C) where the channel is highly colocalized with calnexin (Fig. 1D). To investigate the impact of Ca\(_{3.2}\)/calnexin interaction on channel function, we performed whole-cell patch-clamp recordings of T-type currents. The co-expression of calnexin with Ca\(_{3.2}\) channels in tsA-201 cells revealed a substantial decrease of T-type currents (Fig. 1E). In addition, in response to a depolarizing pulse to \(-20\) mV, the mean peak Ba\(^{2+}\) current density was decreased by 58\% (\(p < 0.001\)) in calnexin-overexpressing cells (\(-17.3 \pm 1.7 \text{ pA/pF, } n = 42\)) as compared to control cells (\(-41.1 \pm 3.4 \text{ pA/pF, } n = 36\)) (Fig. 1F). The maximum slope conductance (Fig. 1F, inset) was reduced by 53\% (\(p < 0.001\)) in calnexin-overexpressing cells (\(331 \pm 28 \text{ pS/pF, } n = 42\)) as compared to control cells (\(706 \pm 55 \text{ pS/pF, } n = 36\)). Similar results were obtained with hCa\(_{3.1}\) and hCa\(_{3.3}\) channels (Fig. S2).

Immunoblot analysis of HA-hCa\(_{3.2}\) revealed that the decreased T-type conductance in calnexin-overexpressing cells was not accompanied by a diminution of the total expression levels of the channel (Fig. 1G). In contrast, nonstationary noise analysis of T-type currents revealed a significant decrease by 76\% (\(p < 0.001\)) of the number of functional channels expressed at the cell surface (\(\text{N}\)) in calnexin-overexpressing cells (\(74.8 \pm 37.6 \text{ channel/pF, } n = 11\)) as compared to control cells (\(311.8 \pm 38.6 \text{ channel/pF, } n = 12\)) (Fig. S3A–C). However, the unitary conductance (\(\gamma\)) of hCa\(_{3.2}\) channels was enhanced \(-2.5\) fold (\(p < 0.01\)) in cells overexpressing calnexin (4.0 \pm 0.5 pS, \(n = 12\)) as compared to control cells (1.6 \pm 0.2 pS, \(n = 11\)), without additional effects on the opening probability (\(Po\)) of the channel (Fig. S3C). It is worth noting that the unitary channel conductance was obtained from the noise analysis of whole cell current traces recorded in the presence of 5 mM Ba\(^{2+}\) and is thus lower than the unitary conductance obtained from direct single channel recordings that are usually performed using a high concentration of charge carrier (routinely 110 mM Ca\(^{2+}\) or Ba\(^{2+}\)). The unitary conductance of 1.6 pS in the absence of overexpressed calnexin is consistent with previous studies using similar recording conditions and analysis\(^36\). In addition, we observed small alterations in some of the biophysical properties of the channel. For instance, activation and inactivation kinetics of Ca\(_{3.2}\) at \(-20\) mV were slightly slower (\(p = 0.0295\) and \(p = 0.0066\), respectively) in calnexin-overexpressing cells (\(\tau_{\text{act}} = 5.5 \pm 0.6 \text{ ms, } \tau_{\text{inac}} = 22.5 \pm 1.2 \text{ ms, } n = 11\)) as compared to control cells (\(\tau_{\text{act}} = 4.0 \pm 0.5 \text{ ms, } \tau_{\text{inac}} = 18.3 \pm 0.8 \text{ ms, } n = 12\)) and we observed a 5 mV depolarizing shift (\(p < 0.0001\)) of the voltage-dependence of activation in calnexin-overexpressing cells (\(-35.2 \pm 0.6 \text{ mV, } n = 11\)) as compared to control cells (\(-40.0 \pm 0.6 \text{ mV, } n = 12\)).

Altogether, these data support the notion that calnexin participates in the maturation of the hCa\(_{3.2}\) channel and controls its expression at the cell surface.

**Molecular determinants of calnexin interactions with hCa\(_{3.2}\) channels.** To determine the molecular determinants of calnexin/Ca\(_{3.2}\) interaction, we developed mCherry-tagged full-length calnexin (CNX\(\text{AD}\)) and deletion mutants of calnexin corresponding to the luminal (CNX\(\text{AC}\)) and cytosolic regions of
the protein (CNXBD) (Fig. 2A). The transmembrane domain of calnexin was conserved in all constructs in order to preserve ER localization. Confocal images of live tsA-201 cells expressing GFP-tagged calreticulin together with mCherry-tagged calnexin-deletion mutants confirmed that the fusion proteins are effectively expressed in the ER compartment (Fig. 2B). A similar colocalization of mCherry-tagged CNX constructs was also observed with GFP-tagged BiP and with an ER-targeted GFP construct (data not shown). We then investigated by co-immunoprecipitation which region of calnexin is required for the interaction with hCaV3.2 channels. As shown in Fig. 2C, the mCherry-tagged luminal (CNXAC) and cytosolic regions of calnexin (CNXBD) both immunoprecipitated HA-hCaV3.2 from tsA-201 cells. Conversely, HA-tagged hCaV3.2 immunoprecipitated mCherry-tagged CNXAC and CNXBD (Fig. 2D). To examine the impact of CaV3.2/calnexin interactions on the trafficking of T-type channels at the plasma membrane, we performed surface immunostaining of HA-hCaV3.2 expressed in tsA-201 cells along with calnexin-deletion mutants. Confocal images of surface HA-hCaV3.2 are
Figure 2. Calnexin associates with hCa₃.2 channels via multiple interactions. (A) Schematic representation of the topology of CNX (top panel) and the different CNX constructs used including CNX full-length (CNXADF), CNX lacking the cytosolic domain (CNXAC), and CNX lacking the luminal domain (CNXBD) (bottom panel). (B) Confocal images of living tsA-201 cells expressing GFP-tagged calreticulin (green, left column) along with mCherry-tagged CNX constructs (red, middle column). Overlaid images are also shown (right column). (C) Co-immunoprecipitation of hCa₃.2-HA from tsA-201 cells co-transfected with mCherry-tagged CNX deletion constructs. The upper panel shows the result of the co-immunoprecipitation of hCa₃.2-HA with CNX-mCherry constructs using an anti-mCherry antibody. Middle panels show the immunoblots of hCa₃.2-HA and CNX-mCherry constructs using anti-HA and anti-mCherry antibodies, respectively. Actin was used as loading control (lower panel). (D) Co-immunoprecipitation of CNX-mCherry constructs with hCa₃.2-HA. The upper panel shows the result of the co-immunoprecipitation of CNX-mCherry constructs with hCa₃.2-HA using an anti-HA antibody. Middle panels show the immunoblots of CNX-mCherry constructs and hCa₃.2-HA using anti-mCherry and anti-HA antibodies, respectively. Actin was used as loading control (lower panel). *CNX cleaved from the ER signal peptide.
shown in Fig. 3A. Surface expression of HA-hCa3.2 was reduced by 48% (p < 0.05) and 47% (p < 0.05) in cells expressing CNXAC and CNXBD, respectively (Fig. 3B). In contrast, surface expression of the membrane-targeted form of GFP (Lck-GFP), which does not interact with calnexin, was unaffected by the co-expression of calnexin, indicating that the effect of calnexin on surface expression of the channel is not mediated by unspecific saturation of the cellular machinery (Fig. S4). Consistent with a decreased surface expression of hCa3.2 channels in the presence of calnexin constructs, T-type currents were significantly reduced (Fig. 3C). For instance, the mean peak Ba2+ current recorded in response to a depolarizing pulse to −20 mV was decreased by 49% (p < 0.001) and 38% (p < 0.001) in cells expressing CNXAC (−21.1 ± 1.9 pA/pF, n = 41) and CNXBD (−25.7 ± 2.3 pA/pF, n = 42), respectively, as compared to control cells (−41.2 ± 2.0 pA/pF, n = 95) (Fig. 3D). The maximum slope conductance was reduced by 43% (p < 0.001) and 31% (p < 0.001) in cells expressing CNXAC (415 ± 35 pS/pF, n = 41) and CNXBD (489 ± 39 pS/pF, n = 42), respectively, as compared to control cells (732 ± 34 pS/pF, n = 95) (Fig. 3D). In contrast, expression of an ER-targeted construct that does not have biological function (ER-dsRed) had no significant effect on T-type currents, indicating that the decreased conductance observed in the presence of calnexin–deletion mutants is not mediated by a non-specific stress of the ER that could have resulted from overexpression, but rather from the specific binding of calnexin regions with hCa3.2 and the retention of the channel in the ER. This notion is further supported by our observation that uncoupling of hCa3.2 channels from...
calnexin by co-expression of the mCherry-calnexin C-tail (CNXCD) fusion protein produced a robust increase of T-type currents (Fig. 4A,B). For instance, in response to a depolarizing pulse to −20 mV, the mean peakBa2+ current density was increased by 76% (p < 0.001) in cells expressing CNXCD (−58.4 ± 3.9 pA/pF, n = 48) as compared to control cells (−33.2 ± 2.4 pA/pF, n = 47) (Fig. 4C). The maximum slope conductance (Fig. 4C, inset) was increased by 70% (p < 0.001) in CNXCD-expressing cells (1028 ± 61 pS/pF, n = 48) as compared to control cells (607 ± 41 pS/pF, n = 47). Consistent with the notion that the increased T-type conductance in the presence of the calnexin C-tail arose from the uncoupling of CaV3.2 from calnexin and thus increased trafficking of the channel to the plasma membrane, the surface expression of HA-tagged CaV3.2 channels assessed by immunostaining was increased by 30% (p < 0.001) in cells expressing the calnexin C-tail (Fig. 4D-E). In contrast, calnexin C-tail had no effect on the total expression of the channel protein. Because the elevated T-type conductance in the presence of calnexin C-tail could also have resulted from a decrease of channel internalization rather than from an increase of the trafficking of the channel to the plasma membrane, we assessed internalization kinetics of HA-hCaV3.2 channels expressed alone (black, n = 3) and in combination with CNXCD (red, n = 3), assessed from non-permeabilized and permeabilized cells, respectively. (F) Internalization kinetics at 37 °C of hCaV3.2-HA channels expressed alone (black, n = 3) and in combination with CNXCD (red, n = 3). The inset indicates the time constant τ of internalization.

Collectively, these results indicate that various regions of calnexin are engaged in the interaction with hCaV3.2 channels. Of particular interest is the demonstration that interactions with the cytosolic calnexin C-tail are involved in the retention of hCaV3.2 in the ER, thus restricting surface expression of the channel.
The calnexin C-tail associates with the III-IV linker region of hCa_{3.2} channels. To identify the Ca_{3.2} molecular determinants of calnexin interactions, we assessed the ability of different intracellular regions of hCa_{3.2} to interact with calnexin C-tail. The main intracellular regions of hCa_{3.2} channels fused to the GFP (Fig. 5A) were expressed in tsA-201 cells together with the mCherry-tagged calnexin C-tail (mCherry-CNIXBD). As shown in Fig. 5B, the calnexin C-tail was specifically immunoprecipitated with the III-IV linker region of hCa_{3.2}. A similar observation was made with the calnexin C-tail deleted of the ER transmembrane domain (mCherry-CNIXCD) indicating that the transmembrane domain is not required for this interaction (Fig. S5). Interestingly, the GAERS mutation correlating with absence seizures in GAERS is located within exon 24 of Cacna1h that encodes the proximal region of the III-IV linker. This missense mutation produces an arginine to proline switch (R1584P) that could potentially affect the electrostatic potential and/or tertiary structure of the III-IV linker and alter protein-protein interactions. To investigate whether the binding of calnexin C-tail is altered by the GAERS mutation, we introduced the homologous mutation (R1573P) into the human III-IV linker. In addition, we generated a III-IV linker construct containing a human mutation (T1606M) previously identified in patients with generalized non-motor epilepsies2° (Fig. 5C, inset). Co-immunoprecipitations from tsA-201 cells expressing the GFP-tagged III-IV variants together with mCherry-tagged calnexin C-tail (mCherry-CNIXBD) revealed a substantially decreased interaction of the calnexin C-tail with the III-IV variant containing the GAERS mutation (Fig. 5C). Indeed, the ability of III-IV R1573P to immunoprecipitate calnexin C-tail was decreased by 70% (p < 0.001) as compared to the wild-type III-IV linker (Fig. 5D). In contrast, the T1606M mutation did not have a significant effect, although there did appear to be a trend towards a weakening interaction. To further support the notion that Ca_{3.2}/calnexin interaction is altered by the GAERS mutation, we performed co-immunoprecipitation experiments of Ca_{3.2} with calnexin from GAERS brain compared to its non-epileptic control (NEC) strain. Consistent with co-immunoprecipitation studies with the calnexin C-tail and Ca_{3.2} III-IV linker, co-immunoprecipitations from GAERS brain homogenates revealed a substantial decrease of the interaction of Ca_{3.2} with calnexin (Fig. 5E) in GAERS brain by 42% (p < 0.01) compared to NEC brain (Fig. 5F).

Altogether, these data identified the III-IV linker region of Ca_{3.2} as the channel region engaged in the interaction with calnexin C-tail, and indicate that this interaction is disrupted by the GAERS Ca_{3.2} missense mutation.

The GAERS mutation alters surface expression of Ca_{3.2} channels by modulating calnexin interactions. It is possible that the decrease in calnexin C-tail binding to the human Ca_{3.2} III-IV linker region carrying the equivalent GAERS mutation may be channel splice variant specific. We thus examined the effect of the GAERS mutation on the III-IV linker of the two major Ca_{3.2} channel splice variants expressed in the rat thalamus, Ca_{3.2} (+25) and Ca_{3.2} (−25), which differ in the presence or absence of the exon 25. This exon encodes a short stretch of six amino acid residues and is located 14 residues downstream the GAERS mutation (Fig. 6A). Consistent with our previous observation, the binding of calnexin C-tail to the rII-III linker (+25) containing the GAERS mutation was significantly decreased by 82% (p < 0.001) compared to the wild-type rIII-IV +/- (25) (Fig. 6B and C). In addition, the binding of calnexin C-tail to the short wild-type rII-III linker variant (−25) was also significantly decreased by 75% (p < 0.001). Introducing the GAERS mutation in the rII-III linker (−25) variant produced an additional 69% decrease (p < 0.01) in binding to the calnexin C-tail compared to wild-type rII-III’ (+25). To establish whether the decrease in the calnexin C-tail interaction with the rCa_{3.2} III-IV linker also alters surface expression of full-length rCa_{3.2} channels, we examined T-type currents in cells expressing various channel variants together with overexpressed full-length calnexin. T-type currents recorded from tsA-201 cells expressing the rCa_{3.2} (+25) channel isoform were significantly increased when the GAERS mutation was introduced (Fig. 6D and E). The maximal conductance was increased by 67% (p < 0.01) in rCa_{3.2}GAERS (+25)-expressing cells (283 ± 30 pS/pF, n = 21) as compared to cells expressing the wild-type rCa_{3.2} (+25) channel (169 ± 20 pS/pF, n = 20) (Fig. 6F). In addition, and consistent with our observation that binding of calnexin C-tail is enhanced in the presence of exon 25, T-type currents recorded from cells expressing the rCa_{3.2} (−25) channel variant were elevated (Fig. 6D and E). For instance, the maximal conductance was increased by 60% (p < 0.01) in rCa_{3.2} (−25)-expressing cells (270 ± 20 pS/pF, n = 23), and by 133% (p < 0.01) in rCa_{3.2}GAERS− (−25)-expressing cells (393 ± 65 pS/pF, n = 21) (Fig. 6F). Remarkably, the electrophysiological data in Fig. 6F appear to be inversely correlated with the biochemical measurements in Fig. 6C, suggesting the possibility that the differences in cell surface expression of the various constructs is mediated by their differential interactions with calnexin. To test this hypothesis, we co-expressed the different rCa_{3.2} channel variants with the calnexin C-tail peptide to disrupt calnexin regulation of Ca_{3.2} channels. Preventing calnexin interactions with the channel not only eliminated the differences in current densities observed with the two exon 25 splice isoforms, but importantly also ablated the effects of the GAERS mutation. (Fig. 6G–I). Altogether, these data indicate that calnexin mediated ER retention of Ca_{3.2} channels is a key determinant of the differential cell surface expression of Ca_{3.2} III-IV linker splice isoforms and are essential for the functional effects of the GAERS mutation.

Discussion Here, we describe a new regulatory pathway for low-voltage-activated T-type Ca^{2+} channels, and provide insights into molecular basis that may underlie the enhancement of T-type Ca^{2+} conductance of thalamic neurons in the Genetic Absence Epilepsy Rat from Strasbourg (GAERS) and other rodent models of absence epilepsy. Our data show that the III-IV linker region of Ca_{3.2} channels interacts with calnexin to increase ER retention of the channel. Of particular importance, our data revealed that the GAERS mutation critically alters the interaction of calnexin with Ca_{3.2}, resulting in a significant increase in surface expression of the channel, which may account for the elevated T-type Ca^{2+} conductance in GAERS reticular thalamic neurons. Using a combination of biochemical and electrophysiological approaches, we revealed that binding of calnexin to Ca_{3.2} has two important consequences. First, it increases the retention of the channel in the ER, resulting in...
Figure 5. The calnexin C-tail associates with the intracellular III-IV linker of hCa3.2. (A) Schematic representation of the different constructs corresponding to the main intracellular regions of hCa3.2. (B) Co-immunoprecipitation of CNX C-tail (CNX<sup>RD</sup>-mCherry) from tsA-201 cells with the main intracellular domains of hCa3.2. The upper panel shows the result of the co-immunoprecipitation of CNX<sup>RD</sup>-mCherry with hCa3.2-GFP constructs using an anti-GFP antibody. Middle panels show the immunoblots of hCa3.2-GFP constructs and CNX<sup>RD</sup>-mCherry using anti-GFP and anti-mCherry antibodies, respectively. Actin was used as loading control (lower panel). (C) Co-immunoprecipitation of CNX C-tail (CNX<sup>RD</sup>-mCherry) from tsA-201 cells with hCa3.2 III-IV linkers carrying the rat GAERS and human epilepsy mutations. The upper panel shows the result of the co-immunoprecipitation of CNX<sup>RD</sup>-mCherry with hCa3.2 III-IV-GFP variants using an anti-GFP antibody. Lower panels show the immunoblots of CNX<sup>RD</sup>-mCherry and hCa3.2 III-IV-GFP using anti mCherry and anti-GFP antibodies, respectively. Inset shows the location of the rat GAERS (red circle) and human epileptic mutations (green circle) in the human Cav3.2 channel. Note that the GAERS R1584P mutation in the rat Cav3.2 channel is equivalent to the R1573P mutation in the human channel. (D) Corresponding mean binding values of CNX<sup>RD</sup>-mCherry on hIII-IV<sup>WT</sup> (black bar) and on hIII-IV<sup>R1573P</sup> (GAERS, red bar) and hIII-IV<sup>T1606M</sup> (green bar) variants (n = 7). The CNX<sup>RD</sup>-mCherry signal was quantified by densitometry using ImageJ software and normalized to the expression level of the corresponding III-IV-GFP used to immunoprecipitate calnexin. (E) Co-immunoprecipitation of Ca<sub>3.2</sub> from NEC versus GAERS brain homogenates with specific anti-calnexin antibody. Corresponding normalized mean binding values of Ca<sub>3.2</sub> on calnexin in NEC (black bar) and GAERS brains (red bar). The Ca<sub>3.2</sub> signal was normalized to the corresponding immunoprecipitated calnexin signal. Data are presented as mean ± SEM and were normalized to total C-tail expression levels and analyzed by one-way ANOVA with Tukey’s post tests; NS not significant, **p < 0.01, ***p < 0.001.
decreased expression of T-type channels at the cell surface without alteration of the total protein levels. Second, it participates in the maturation/folding of Ca\textsubscript{v}3.2 channels as evidenced by an increase of the single channel conductance in the presence of overexpressed calnexin. The increased channel conductance may result from an improved folding of the channel consistent with the chaperone role of calnexin in the maturation of newly synthetized proteins. It is also conceivable that increased ER retention of Cav3.2 alters the glycosylation status of the channel, which in turn may affect ion permeability. Consistent with this idea, we have recently reported that N-linked glycosylation of hCav3.2 at specific loci influences channel permeability\textsuperscript{38}. Nonetheless, the net effect of calnexin interactions with the channel is a decrease of Ca\textsubscript{v}3.2 surface expression, consistent with a reduction of the whole cell Ca\textsuperscript{2+} conductance. These results support the existence of a Ca\textsubscript{v}3.2/calnexin signaling complex that is essential for the maturation and sorting of T-type channels to the cell surface, similar to that for Na\textsubscript{v}1.8 channels, CFTR channels, Shaker potassium channels, and other G-protein coupled receptors including acetylcholine and dopamine D1 and D2 receptors\textsuperscript{39–44}.

Figure 6. The GAERS epilepsy mutation alters surface trafficking of Ca\textsubscript{v}3.2 channels. (A) Schematic representation of the rat Ca\textsubscript{v}3.2 III-IV linker variants. The exon 25 contained in the III-IV linker is alternatively spliced to generate rCa\textsubscript{v}3.2 (+25) and rCa\textsubscript{v}3.2 (−25) channels. The GAERS mutation R1584P located upstream the exon 25 is highlighted in red. (B) Co-immunoprecipitation of CNX C-tail (CNX\textsuperscript{BD-mCherry}) from tsA-201 cells with rat Ca\textsubscript{v}3.2 III-IV-GFP variants. The upper panel shows the result of the co-immunoprecipitation CNX\textsuperscript{BD-mCherry} with rat Ca\textsubscript{v}3.2 III-IV-GFP variants using an anti-GFP antibody. Middle panels show the immunoblots of CNX\textsuperscript{BD-mCherry} and rCa\textsubscript{v}3.2 III-IV-GFP using anti mCherry and anti-GFP antibodies, respectively. Actin was used as loading control (lower panel). (C) Corresponding mean binding values of CNX\textsuperscript{BD-mCherry} on rCa\textsubscript{v}3.2 WT (black bar) and GAERS-III-IV linker (red bar) containing exon 25, and on WT- (green bar) and GAERS-III-IV linker (blue bar) lacking of the exon 25. The data were normalized to total C-tail expression levels. (D and E) Mean current/voltage relationship of T-type currents recorded from tsA-201 cells expressing rCa\textsubscript{v}3.2 WT (+25) (black circles, \(n = 20\)), rCa\textsubscript{v}3.2\textsuperscript{GAERS} (+25) (red circles, \(n = 21\)), rCa\textsubscript{v}3.2\textsuperscript{WT} (−25) (green circles, \(n = 23\)), and rCa\textsubscript{v}3.2\textsuperscript{GAERS} (−25) (blue circles, \(n = 21\)). (F) Corresponding normalized mean maximum slope conductance \(G_{\text{max}}\) values. (G, H and I) Same as in (D and E) but for cells expressing the calnexin C-tail peptide. Data are presented as mean ± SEM and were analyzed by one-way ANOVA with Tukey’s posttests; NS not significant, \(*p < 0.05\), \(**p < 0.01\), \(***p < 0.001\).
Detailed analysis of the molecular determinants of the CaV3.2/calnexin interaction revealed that CaV3.2 interacts with two distinct calnexin regions. In part, CaV3.2 interacts with the ER luminal domain of calnexin. It is well known that this domain is responsible for lectin-like activity of calnexin and glycosylation-dependent interaction with newly synthesized glycoproteins. Although this interaction has not been investigated in more detail in the current study, it likely involves one or more extracellular regions of the channel (i.e. facing the lumen side when the channel is embedded in the membrane of the ER) located in domains I, II and IV that are known to be N-glycosylated. In another part, CaV3.2 interacts with the cytosolic region of calnexin (calnexin C-tail) via its domain III-IV cytosolic linker. We showed that this interaction is sufficient to mediate the retention of CaV3.2 in the ER and to decrease the sorting of channels to the cell surface. Conversely, uncoupling calnexin from its binding site on the channel via coexpression of the calnexin C-tail interfering peptides resulted in a significant increase in the surface expression of the channel. While little is known about the cellular functions of the calnexin C-tail, a role in the control of clathrin-mediated endocytosis of membrane proteins has been proposed. However, our observation that internalization properties of CaV3.2 channels were not affected by the presence of the calnexin C-tail strongly supports the notion that the increased channel surface expression is the direct consequence of a decreased ER retention of the channel upon uncoupling of CaV3.2 from calnexin.

The steady-state expression of T-type channels at the cell surface is governed by a balance between the number of channels arriving at and being removed from the plasma membrane. Hence, our observation that calnexin affects the sorting of T-type channels to the cell surface may have important consequences on neuronal excitability. Indeed, we have revealed a previously unrecognized effect of the GAERS CaV3.2 missense mutation on the trafficking of CaV3.2 channels. Of particular interest is the observation that the GAERS mutation alters the binding of calnexin C-tail to the III-IV linker region of CaV3.2, resulting in a potent increase of the expression of channels at the cell surface. The observation that CaV3.2 surface expression by altering calnexin-dependent ER retention of the channel provides a further explanation to the hyperexcitability observed in a subset of GAERS thalamic neurons and believed to underlie absence seizures. A modest increase of CaV3.2 mRNA levels has also been reported in GAERS, but whether this correlates with an increased expression levels of the channel and/or is a result of further underlying genetic alterations remains to be investigated.

It is established that alternative splicing represents an important mechanism that controls the expression and regulation of ion channels including T-type channels. CaV3.2 splice variants with distinct biophysical properties have previously been identified in the rat thalamus and that differ by the presence or absence of exon 25 encoding for a small region of the III-IV linker region. Our study revealed that binding of calnexin C-tail on the III-IV linker lacking the exon 25 is significantly decreased, which correlated with an increased expression of the CaV3.2 (–25) channel variant at the cell surface. This observation further supports the notion that CaV3.2/calnexin interaction plays an essential role in the control of surface trafficking of the T-type channel. It also uncovers a new mechanism by which alternative splicing of CaV3.2 can affect channel surface expression. In addition, the surface expression of the CaV3.2 (–25) variant was further augmented in the presence of the GAERS CaV3.2 missense mutation. Of note, the observed splice-variant specific effects of calnexin interactions on CaV3.2 current conductance are quantitatively analogous to that for the previously described splice-variant effects of the GAERS mutation on CaV3.2 recovery from inactivation. Together, these data suggest that GAERS neuronal hyperexcitability and seizure activity may result from a combination of gain-of-functions derived from domain III-IV linker splice variant CaV3.2/calnexin interactions and splice variant specific effects of the GAERS CaV3.2 missense mutation on recovery from inactivation. It remains to be determined whether the GAERS genome possess any further underlying genetic alterations associated with the CaV3.2/calnexin interactions and that could further affect T-type calcium channel functioning or that of other ion channels.

Alteration of T-type channel expression has been linked to various neurological disorders including absence epilepsy. Interestingly, the III-IV linker region of CaV3.2 channels has previously been implicated in the control of channel activation and recovery from inactivation, as well as in the control of channel expression by ubiquitination. Here, we present evidence that the III-IV linker also mediates calnexin-dependent control of channel surface expression. Hence, the III-IV linker region of CaV3.2 channels, albeit relatively short compared to the other intracellular region of the channel, appears to be an essential hub for regulating key aspects of calcium channel trafficking and biophysical properties. The physiological importance of this regulatory hotspot is underscored by its role in chronic pain and as we show here, seizure disorders.

Materials and Methods
Plasmids cDNA constructs. The human wild-type HA-CaV3.2 construct (HA-hCaV3.2WT) was previously described. This plasmid was used as a template to amplify by PCR the main cytoplasmic regions of the channel (amino- and carboxy-terminal regions, I-II, II-III, and III-IV linkers), and the PCR products were inserted into the Xhol/HindIII sites of pEGFP-C1 vector. The GFP-tagged III-IV linker construct was used as a template to introduce by site-directed mutagenesis the R1573P and T1606M mutations using overlap extension PCR method, and the PCR products were inserted into the Xhol/HindIII sites of pEGFP-C1 vector. The wild-type and GAERS CaV3.2 ± exon 25 variants in pcDNA3.1 were previously described. Sequences encoding the various rat III-IV linkers used in this study were synthesized in vitro (GenScript) and subcloned into the Xhol/ HindIII sites of pEGFP-C1 vector. To generate mCherry-tagged calnexin constructs, plasmids encoding for the full-length mouse calnexin (CNXAD) and calnexin fragments (CNXAC and CNXBD) were used as template for PCR. PCR products encoding for the different domains of calnexin and mCherry were inserted into KpnI/AgeI sites and AgeI/Pmel sites of pcDNA3.1 (+) vector, respectively, to generate C-terminal mCherry-tagged calnexin constructs. The PCR primers used to generate those constructs are shown in Supplementary Information. All final constructs were verified by sequencing of the full-length cDNAs. The Lck-GFP construct encoding for a membrane-targeted form of GFP was previously described.
Heterologous expression. Human embryonic kidney tsA-201 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen), and maintained under standard conditions at 37 °C in a humidified atmosphere containing 5% CO₂. Cells were transiently transfected using the calcium phosphate method.

Patch-clamp electrophysiology. Patch-clamp recordings were performed 72 h after transfection in the whole-cell configuration of the patch-clamp technique at room temperature (22–24 °C) as previously described55. Briefly, the bath solution contained (in millimolar): 5 BaCl₂, 5 KCl, 1 MgCl₂, 128 NaCl, 10 TEA-Cl, 10 D-glucose, 10 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH7.2 with NaOH). Patch pipettes had a resistance of 2–4 MΩ when filled with a solution containing (in millimolar): 110 CsCl, 3 Mg-ATP, 0.5 Na-GTP, 2.5 MgCl₂, 5 D-glucose, 10 EGTA, and 10 HEPES (pH7.4 with CsOH). Whole-cell patch-clamp recordings were performed using an Axopatch 200B amplifier (Axon Instruments). Acquisition and analysis were performed using pClamp 9 and Clampfit 9 software, respectively (Axon Instruments). All traces were corrected online for leak currents, digitized at 10 kHz, and filtered at 2 kHz. The voltage dependence of the peak Ba²⁺ current density was fitted with the following modified Boltzmann equation (1):

\[ I(V) = \frac{G_{\text{max}}}{1 + \exp\left(\frac{V - V_{\text{rev}}}{k}\right)} \]  

(1)

with \( I(V) \) being the peak current amplitude at the command potential \( V \), \( G_{\text{max}} \) the maximum conductance, \( V_{\text{rev}} \) the reversal potential, \( V_{0.5} \) the half-activation potential, and \( k \) the slope factor. The voltage dependence of the whole-cell Ba²⁺ conductance was calculated using the following modified Boltzmann equation (2):

\[ G(V) = \frac{G_{\text{max}}}{1 + \exp\left(\frac{V - V_{0.5}}{k}\right)} \]  

(2)

with \( G(V) \) being the Ba²⁺ conductance at the command potential \( V \).

Immunoprecipitation. Co-immunoprecipitation experiments were performed 72 h after transfection. Cells were lysed in NP40 lysis buffer (50 mM Tris, 150 mM NaCl, 1% NP40, pH 8.0), incubated for 30 min at 4 °C, and centrifuged for 30 min at 15,000 RPM. The protein concentration was estimated using a Bradford Protein Assay (BioRad). For co-immunoprecipitation experiments, 1 mg/mL total cell lysate was incubated overnight at 4 °C with 2 μg of “catching” antibody (mouse monoclonal anti-GFP (Abcam), rat monoclonal anti-HA (Roche), mouse monoclonal anti-mCherry, or rabbit polyclonal anti-Ca v3.2 (Alomone)). For co-immunoprecipitation of native proteins, 10% rat brain homogenate was prepared in lysis buffer (50 mM TrisHCl pH 8.0, 300 mM NaCl, 0.5% Triton ×100, 0.5% DOC, Protease Inhibitors without EDTA) and stored as aliquots of 500 μL at −80 °C. For co-immunoprecipitation, 500 μL of lysis buffer without detergent and 2 μg of “catching” antibody (rabbit polyclonal anti-CNX (Abcam) or rabbit polyclonal anti-Ca v3.2 (Santa Cruz)) were added to the 10% brain homogenate samples and incubated overnight at 4 °C. Samples were then incubated with 30 μL (50 μL slurry) Sepharose G beads for 2 h at 4 °C. Beads were centrifuged for 1 min at low speed, washed three times (20 μM Tris, 300 mM NaCl, 0.1% Tween-20, pH 8.0), and incubated with 30 μL Laemmli buffer.

SDS-PAGE and immunoblot analysis. Immunoprecipitation samples, or total lysates (25 μg), were separated on 12% SDS-PAGE and transferred onto PVDF membrane (Millipore). For detection of the HA-hCa v3.2 channel, the membrane was incubated with a primary rat monoclonal anti-HA antibody (Roche) diluted at 1:1000; GFP-tagged hCa v3.2 loops were detected with a primary rat monoclonal anti-GFP antibody (Abcam) diluted at 1:11,000; mCherry-tagged calnexin was detected with a primary mouse monoclonal anti-mCherry antibody (Abcam) diluted at 1:11,000; native calnexin was detected using a primary rabbit polyclonal anti-calnexin antibody (Abcam) diluted at 1:5000. For detection of native proteins, the following antibodies were used and incubated overnight at 4 °C with the membrane: rabbit polyclonal anti-Ca v3.2 antibody (Santa Cruz) diluted at 1:5000; mouse monoclonal anti-BiP antibody diluted at 1:10,000; mouse monoclonal anti-β1 integrin antibody (Santa Cruz) diluted at 1:10,000; rabbit monoclonal anti-calreticulin antibody (Santa Cruz) diluted at 1:10,000; and rabbit polyclonal anti-calnexin antibody (Abcam) diluted at 1:10,000, incubated overnight at 4 °C. Membranes were then washed in PBS/TWEEN-20 buffer, and incubated with the corresponding secondary HRP-conjugated antibody (Jackson ImmunoResearch) diluted at 1:20,000. For immunoprecipitation controls, membranes were stripped to remove antibodies in a stripping buffer (0.2 M glycine, 1% SDS; pH 2.0) and then rebotted as described above. Immunoreactive bands were detected by enhanced chemiluminescence.

Surface immunostaining. Twenty-four hours before the experiment, cells expressing HA-Ca v3.2 channels were seeded on poly-L-lysine-coated glass coverslips. Cells were incubated for 30 min at 37 °C with a primary monoclonal mouse anti-HA antibody (Abcam) diluted at 1:1000, washed with PBS, fixed for 7 min in 4% paraformaldehyde, and blocked for 45 min in blocking buffer (5% FBS in PBS). Cells were then incubated for 1 h at room temperature with a secondary goat polyclonal anti-mouse Alexa488-conjugated antibody (Jackson ImmunoResearch) diluted in blocking buffer at 1:1000, washed, and mounted on microscope glass slides with ProLong Gold mounting medium (Life Technologies). Confocal images were acquired with a Zeiss LSM780 microscope and the field fluorescence intensity was analyzed using ImageJ software.
For internalization studies, cells were incubated with a primary anti-HA antibody as described above, washed, kept at 37 °C for 30, 60, 120, or 180 min to allow internalization of the channel, fixed, and stained with a secondary Alexa488-conjugated antibody to assess the time-dependence of surface expression of the channel. In order to visualize internalized channels, cells were permeabilized with 0.2% Triton X-100 for 10 min before incubation with the secondary antibody.

**Statistical analysis.** Data values are presented as mean ± S.E.M. for n experiments. Statistical significance was determined using Student's unpaired t test or one-way ANOVA with Tukey's post tests as indicated in the figure legends: *p < 0.05, **p < 0.01, ***p < 0.001, and NS, statistically not different.

**References**

1. Myers, C. T. & Mefford, H. C. Advancing epilepsy genetics in the genomic era. *Genome Med* 7, 91 (2015).
2. Seneviratne, U., Cook, M. & D’Souza, W. The electroencephalogram of idiopathic generalized epilepsy. *Epilepsia* 53, 234–248 (2012).
3. Hughes, J. R. Absence seizures: a review of recent reports with new concepts. *Epilepsy Behav* 15, 404–412 (2009).
4. Marescau, C. et al. A model of chronic spontaneous petit mal-like seizures in the rat: comparison with pentylenetetrazol-induced seizures. *Epilepsia* 25, 326–331 (1984).
5. Marescau, C., Vergnes, M. & Depaulis, A. Genetic absence epilepsy in rats from Strasbourg—a review. *J Neurotransm Suppl* 35, 37–69 (1992).
6. Powell, K. L. et al. A Cav3.2 T-type calcium channel point mutation has splice-variant-specific effects on function and segregates with seizure expression in a polygenic rat model of absence epilepsy. *J Neurosci* 29, 371–380 (2009).
7. Perez-Reyes, E. Molecular physiology of low-voltage-activated t-type calcium channels. *Physiol Rev* 83, 117–161 (2003).
8. Crunelli, V., Cope, D. W. & Hughes, S. W. Thalamic T-type Ca2+ channels and NREM sleep. *Cell Calcium* 40, 175–190 (2006).
9. Bal, T. & McCormick, D. A. Synchronised oscillations in the inferior olive are controlled by the hyperpolarization-activated cation current (Ih). *J Neurophysiol* 77, 3145–3156 (1997).
10. Beurrier, C., Congar, P., Bouilacq, B. & Hammond, C. Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode. *J Neurosci* 19, 599–609 (1999).
11. Sotty, F. et al. Distinct electrophysiological properties of glutamatergic, cholinergic and GABAergic rat septohippocampal neurons: novel implications for hippocampal rhythmicity. *J Physiol* 551, 927–943 (2003).
12. Crunelli, V. & Lerescu, N. Childhood absence epilepsy: genes, channels, neurons and networks. *Nat Rev Neurosci* 3, 371–382 (2002).
13. Budde, T. et al. Impaired regulation of thalamic pacemaker channels through an imbalance of subunit expression in absence epilepsy. *J Neurosci* 25, 9871–9882 (2005).
14. Cain, S. M. & Snutch, T. P. T-type calcium channels in burst-firing, network synchrony, and epilepsy. *Biochim Biophys Acta* 1282, 1573–1578 (2003).
15. Chen, Y. et al. Association between genetic variation of CACNA1H and childhood absence epilepsy. *Ann Neurol* 54, 239–243 (2003).
16. Khosravani, H. et al. Gating effects of mutations in the Cav3.2 T-type calcium channel associated with childhood absence epilepsy. *J Biol Chem* 279, 9681–9684 (2004).
17. Khosravani, H. et al. Effects of Cav3.2 channel mutations linked to idiopathic generalized epilepsy. *Ann Neurol* 57, 745–749 (2005).
18. Vito, I. et al. Functional characterization and neuronal modeling of the effects of childhood absence epilepsy variants of CACNA1H, a T-type calcium channel. *J Neurosci* 25, 4844–4855 (2005).
19. Peloquin, J. B. et al. Functional analysis of Ca3.2 T-type calcium channel mutations linked to childhood absence epilepsy. *Epilepsia* 47, 655–658 (2006).
20. Heron, S. E. et al. Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. *Ann Neurol* 62, 560–568 (2007).
21. Tringham, E. et al. T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures. *Sci Transl Med* 4, 121ra19 (2012).
22. Powell, K. L., Cain, S. M., Snutch, T. P. & O’Brien, T. J. Low threshold T-type calcium channels as targets for novel epilepsy treatments. *Br J Clin Pharmacol* 77, 729–739 (2014).
23. Casillas-Espinosa, P. M. et al. 294, A Novel Selective T-Type Calcium Channel Antagonist Delays the Progression of Seizures in the Amygdala Kindling Model. *PLoS One* 10, e0130012 (2015).
24. Zamponi, G. W. Targeting voltage-gated calcium channels in neurological and psychiatric diseases. *Nat Rev Drug Discov* 15, 19–34 (2016).
25. Tsakiridou, E., Bertollini, L., de Curtis, M., Avanzini, G. & Pape, H. C. Selective increase in T-type calcium conductance of reticular thalamic neurons in a rat model of absence epilepsy. *J Neurosci* 35, 3110–3117 (2015).
26. Zhang, Y., Mori, M., Burgess, D. L. & Noebels, J. L. Mutations in high-voltage-activated calcium channel genes stimulate low-voltage-activated currents in mouse thalamic relay neurons. *J Neurosci* 22, 6362–6371 (2002).
27. Zhang, Y., Vilaythong, A. P., Yoshor, D. & Noebels, J. L. Elevated thalamic low-voltage-activated currents precede the onset of absence epilepsy in the SNAP25-deficient mouse mutant coloboma. *J Neurosci* 24, 5239–5248 (2004).
28. Kim, D. et al. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking alpha(1G) T-type Ca2(+) channels. *Neuron* 31, 35–45 (2001).
29. Ernst, W. L., Zhang, Y., Yoo, J. W., Ernst, S. J. & Noebels, J. L. Genetic enhancement of thalamocortical network activity by elevating alpha 1-mediated low-voltage-activated calcium current induces pure absence epilepsy. *J Neurosci* 29, 1615–1625 (2009).
30. Talley, E. M., Solorzano, G., Depaulis, A., Perez-Reyes, E. & Bayliss, D. A. Low-voltage-activated calcium channel subunit expression in a genetic model of absence epilepsy in the rat. *Molecular Brain Research* 79, 159–165 (2000).
31. Illggaard, L. & Helenius, A. Quality control in the endoplasmic reticulum. *Nat Rev Mol Cell Biol* 4, 181–191 (2003).
32. Weiss, N., Black, S. A., Bladen, C., Chen, L. & Zamponi, G. W. Surface expression and function of Cav3.2 T-type calcium channels are controlled by asparagine-linked glycosylation. * Pfugers Arch* 465, 1159–1170 (2013).
33. Lazzniewska, J. & Weiss, N. The “sweet” side of ion channels. *Rev Physiol Biochem Pharmacol* 167, 67–114 (2014).
34. Lazzniewska, J., Rzhepetskyy, Y., Zhang, F. X., Zamponi, G. W. & Weiss, N. Cooperative roles of glucose and asparagine-linked glycosylation in T-type calcium channel expression. *Pfugers Arch* 468, 1837–1851 (2016).
35. Lazzniewska, J. & Weiss, N. Glycosylation of voltage-gated calcium channels in health and disease. *Biochim Biophys Acta* 1859, 662–668 (2017).
36. Aromolaran, K. A., Benzow, K. A., Cribbs, L. L., Koob, M. D. & Piedras-Renteria, E. S. T-type current modulation by the actin-binding protein Kelch-like 1. *Am J Physiol Cell Physiol* 298, C1533–62 (2010).
37. Li, H. D., Liu, X. Y. & Michalak, M. Enhanced clathrin-dependent endocytosis in the absence of calnexin. *PLoS One* 6, e21678 (2011).
38. Ondacova, K., Karmazinova, M., Lazzniewska, J., Weiss, N. & Lacinova, L. Modulation of Cav3.2 T-type calcium channel permeability by asparagine-linked glycosylation. *Channels (Austin)* 10, 175–184 (2016).
39. Keller, S. H., Lindstrom, J. & Taylor, P. Involvement of the chaperone protein calnexin and the acetylcholine receptor beta-subunit in the assembly and cell surface expression of the receptor. *J Biol Chem* **271**, 22871–22877 (1996).

40. Gelman, M. S., Chang, W., Thomas, D. Y., Bergeron, J. J. & Prives, J. M. Role of the endoplasmic reticulum chaperone calnexin in subunit folding and assembly of nicotinic acetylcholine receptors. *J Biol Chem* **270**, 15085–15092 (1995).

41. Okiyoneda, T. *et al.* Role of calnexin in the ER quality control and productive folding of CFTR; differential effect of calnexin knockout on wild-type and DeltaF508 CFTR. *Biochim Biophys Acta* **1783**, 1585–1594 (2008).

42. Higgins, M. K., Demir, M. & Tate, C. G. Calnexin co-expression and the use of weaker promoters increase the expression of correctly assembled Shaker potassium channel in insect cells. *Biochim Biophys Acta*** **1610**, 124–132 (2003).

43. Free, R. B. *et al.* D1 and D2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin. *J Biol Chem* **282**, 21285–21300 (2007).

44. Li, Q. *et al.* Transmembrane segments prevent surface expression of sodium channel Nav1.8 and promote calnexin-dependent channel degradation. *J Biol Chem* **285**, 32977–32987 (2010).

45. Keller, S. H., Lindstrom, J. & Taylor, P. Inhibition of glucose trimming with castanospermine reduces calnexin association and promotes proteasome degradation of the alpha-subunit of the nicotinic acetylcholine receptor. *J Biol Chem* **273**, 17064–17072 (1998).

46. Chemin, J., Monteil, A., Bourinot, E., Nargeot, J. & Lory, P. Alternatively spliced alpha1G(Ca(V)3.1) intracellular loops promote specific T-type Ca(2+) channel gating properties. *Biophys J* **80**, 1238–1250 (2001).

47. Murbartij, A., Arias, J. M., Lee, J. H., Gomora, J. C. & Perez-Reyes, E. Alternative splicing of the rat Ca(v)3.3 T-type calcium channel gene produces variants with distinct functional properties. *FEBS Lett* **528**, 272–278 (2002).

48. Murbartij, A., Arias, J. M. & Perez-Reyes, E. Functional impact of alternative splicing of human T-type Cav3.3 calcium channels. *J Neurophysiol* **92**, 3399–3407 (2004).

49. Ohkubo, T., Inoue, Y., Kawarabayashi, T. & Kitamura, K. Identification and electrophysiological characteristics of isoforms of T-type calcium channel Ca(v)3.2 expressed in pregnant human uterus. *Cell Physiol Biochem* **16**, 245–254 (2005).

50. Zhong, X., Liu, J. R., Kyle, J. W., Hanck, D. A. & Agnew, W. S. A profile of alternative RNA splicing and transcript variation of CACNA1H, a human T-channel gene candidate for idiopathic generalized epilepsies. *Hum Mol Genet* **15**, 1497–1512 (2006).

51. David, L. S. *et al.* Splice-variant changes of the Ca(V)3.2 T-type calcium channel mediate voltage-dependent facilitation and associate with cardiac hypertrophy and development. *Channels (Austin)* **4**, 375–389 (2010).

52. García-Caballero, A. *et al.* The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity. *Neuron* **83**, 1144–1158 (2014).

53. Dubeil, S. J. *et al.* Plasma membrane expression of T-type calcium channel alpha1 subunits is modulated by high voltage-activated auxiliary subunits. *J Biol Chem* **279**, 29263–29269 (2004).

54. Benediktsdottir, A. M., Schachtiele, S. J., Green, S. H. & Dailey, M. E. Ballistic labeling and dynamic imaging of astrocytes in organotypic hippocampal slice cultures. *J Neurosci Methods* **141**, 41–53 (2005).

55. Rzhetsky, Y., Lazniewska, J., Blesnac, I., Pamphlett, R. & Weiss, N. CACNA1H missense mutations associated with amyotrophic lateral sclerosis alter Cav3.2 T-type calcium channel activity and reticular thalamic neuron firing. *Channels (Austin)* **10**, 466–477 (2016).

**Acknowledgements**

We are grateful to Dr. Marek Michalak (University of Alberta, Edmonton, Canada) for providing the mouse calnexin cDNA, to Dr. Steven H. Green (University of Iowa, Iowa City, USA) for providing the Lck-GFP construct, and to Dr. Erik Lee Snapp (Albert Einstein College of Medicine) for providing the calreticulin-GFP construct. We thank Drs. Michael Pusch (Institute of Biophysics, Genova, Italy) and Erika S. Piedras-Renteria (Loyola University Chicago, Maywood, USA) for their valuable help with the noise analysis. N.W. is supported by the Czech Science Foundation (15-13556S), the Czech Ministry of Education Youth and Sports (#7AMBI15FR015), and the Institute of Organic Chemistry and Biochemistry (IOCB). J.P. and Y.R. held a postdoctoral fellowship from the IOCB. G.W.Z. is a Canada Research Chair in Molecular Neuroscience and supported by a foundation grant from the Canadian Institutes of Health Research (CIHR). E.X.Z. held a fellowship from Alberta Innovates-Health Solutions. T.P.S. is supported by an operating grant from CIHR (#10677) and the Canada Research Chair in Biotechnology and Genomics-Neurobiology. S.M.C. is supported by a CURE – Taking Flight Award.

**Author Contributions**

Conceptualization, G.W.Z. and N.W.; Methodology, J.P., Y.R., J.L., E.X.Z., S.M.C., T.P.S. and N.W.; Formal Analysis, J.P., J.L., and N.W.; Investigation, J.P., J.L., and N.W.; Writing, T.P.S, G.W.Z, and N.W.; Supervision and Funding, G.W.Z and N.W.

**Additional Information**

Supplementary information accompanies this paper at doi:10.1038/s41598-017-11591-5

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.